Compare MobilEye Global Inc (MBLY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? MobilEye Global Inc trades at $7.32 (market cap $6.08B), while Travere Therapeutics Inc. Common Stock trades at $54.66 (market cap $5.02B). The key difference: MobilEye Global Inc is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MBLY | TVTX | |
|---|---|---|
Market Cap | $6.08B | $5.02B |
Volume | 9,825,806 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.33 | $67.52 |
52-Week Low | $6.56 | $26.79 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.64B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.245, up 3.21% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong revenue growth to $1.89B in 2025 but posted a significant net loss of -$392M, with profitability metrics remaining negative. Recent news highlights ADAS business momentum and strategic investments in autonomous mobility, while analyst consensus leans positive with 57.7% buy ratings.
The stock presents a high-risk opportunity with substantial losses offset by strong revenue growth and market leadership in ADAS. Key catalysts include Porsche launch execution and robotaxi expansion, but investors face execution risks and persistent negative margins. The consensus price target of $10.77 suggests 49% upside potential from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
